Plenary Paper
暂无分享,去创建一个
W. Choi | R. Gascoyne | G. Slack | M. Piris | Wei-min Liu | G. Bhagat | Y. Zu | K. Young | Z. Xu-Monette | L. Medeiros | K. Richards | M. Møller | J. Huh | S. Montes-Moreno | C. Visco | E. Hsi | M. Ponzoni | A. Ferreri | Yong Li | R. Miranda | K. Dybkaer | A. Chiu | R. Go | W. Ai | Weina Chen | A. Tzankov | A. Orazi | D. Variakojis | Shimin Hu | Xiaoying Zhao | Qin Huang | Lin Wu | M. Tu | A. Balasubramanyam | J. Krieken | T. Green | F. Zhou
[1] K. Lam,et al. Molecular Characteristics of CTA056, a Novel Interleukin-2-Inducible T-Cell Kinase Inhibitor that Selectively Targets Malignant T Cells and Modulates Oncomirs , 2012, Molecular Pharmacology.
[2] J. Byrd,et al. The B-cell receptor signaling pathway as a therapeutic target in CLL. , 2012, Blood.
[3] Jeffrey A Jones,et al. A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. , 2012 .
[4] Defeng Wu,et al. Role of Itk signalling in the interaction between influenza A virus and T-cells. , 2012, The Journal of general virology.
[5] R. Baiocchi,et al. Novel targeted therapies for mantle cell lymphoma , 2012, Oncotarget.
[6] C. Harrison. Trial watch: BTK inhibitor shows positive results in B cell malignancies , 2012, Nature Reviews Drug Discovery.
[7] S. Im,et al. Enhanced Chromatin Accessibility and Recruitment of JUNB Mediate the Sustained IL-4 Expression in NFAT1 Deficient T Helper 2 Cells , 2011, PloS one.
[8] W. Robinson,et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells , 2011, Arthritis research & therapy.
[9] Jeffrey A Jones,et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. , 2011, Blood.
[10] P. Schwartzberg,et al. Tec family kinases Itk and Rlk / Txk in T lymphocytes: cross‐regulation of cytokine production and T‐cell fates , 2011, The FEBS journal.
[11] C. I. Smith,et al. TEC family kinases in health and disease – loss‐of‐function of BTK and ITK and the gain‐of‐function fusions ITK–SYK and BTK–SYK , 2011, The FEBS journal.
[12] R. Advani,et al. The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study , 2010 .
[13] Douglas H. Thamm,et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy , 2010, Proceedings of the National Academy of Sciences.
[14] E. Forbes,et al. Differential requirements for IL‐4/STAT6 signalling in CD4 T‐cell fate determination and Th2‐immune effector responses , 2010, Immunology and cell biology.
[15] L. Silvian,et al. Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases , 2010, Protein science : a publication of the Protein Society.
[16] V. Morrison. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. , 2010, Best practice & research. Clinical haematology.
[17] R. Advani,et al. A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay. , 2009 .
[18] A. Sher,et al. Selective Expression Rather than Specific Function of Txk and Itk Regulate Th1 and Th2 Responses1 , 2008, The Journal of Immunology.
[19] J. Byrd,et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. , 2008, The Journal of clinical investigation.
[20] P. Schwartzberg,et al. Selective targeting of ITK blocks multiple steps of HIV replication , 2008, Proceedings of the National Academy of Sciences.
[21] E. Sotomayor,et al. Cellular and molecular mechanisms of tumor-induced T-cell tolerance. , 2007, Current cancer drug targets.
[22] P. Schwartzberg,et al. Altered development of CD8+ T cell lineages in mice deficient for the Tec kinases Itk and Rlk. , 2006, Immunity.
[23] D. Fowell,et al. Cutting Edge: Itk-Dependent Signals Required for CD4+ T Cells to Exert, but Not Gain, Th2 Effector Function1 , 2006, The Journal of Immunology.
[24] L. Atherly,et al. Tec kinases Itk and Rlk are required for CD8+ T cell responses to virus infection independent of their role in CD4+ T cell help. , 2006, The Journal of Immunology.
[25] H. Mellstedt,et al. T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil , 2006, Cancer Immunology, Immunotherapy.
[26] M. Croft,et al. Regulation of dendritic cell maturation and function by Bruton's tyrosine kinase via IL-10 and Stat3. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[27] J. Gribben,et al. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. , 2005, The Journal of clinical investigation.
[28] Heather M. Wilcox,et al. Signaling through Itk promotes T helper 2 differentiation via negative regulation of T-bet. , 2004, Immunity.
[29] C. Cancrini,et al. Bruton's tyrosine kinase defect in dendritic cells from X‐linked agammaglobulinaemia patients does not influence their differentiation, maturation and antigen‐presenting cell function , 2003, Clinical and experimental immunology.
[30] A. Varghese,et al. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. , 2003, Archives of dermatology.
[31] A. Prentice,et al. Abnormal T-cell Function in B-cell Chronic Lymphocytic Leukaemia , 2003, Leukemia & lymphoma.
[32] P. Lydyard,et al. Expansion of CD4+ T cells with a cytotoxic phenotype in patients with B‐chronic lymphocytic leukaemia (B‐CLL) , 2001, Clinical and experimental immunology.
[33] H. Nagafuchi,et al. Txk, a Nonreceptor Tyrosine Kinase of the Tec Family, Is Expressed in T Helper Type 1 Cells and Regulates Interferon γ Production in Human T Lymphocytes , 1999, The Journal of experimental medicine.
[34] R. Coffman,et al. Impaired NFATc translocation and failure of Th2 development in Itk-deficient CD4+ T cells. , 1999, Immunity.
[35] H. Varmus,et al. Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity. , 1999, Science.
[36] S. Bunnell,et al. T Cell Receptor–initiated Calcium Release Is Uncoupled from Capacitative Calcium Entry in Itk-deficient T Cells , 1998, The Journal of experimental medicine.
[37] A. Hoerauf,et al. The Xid defect determines an improved clinical course of murine leishmaniasis in susceptible mice. , 1994, International immunology.
[38] J. Ceuppens,et al. Ligation of the CD5 or CD28 molecules on resting human T cells induces expression of the early activation antigen CD69 by a calcium- and tyrosine kinase-dependent mechanism. , 1993, Immunology.
[39] R. Advani,et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] H. Lo. Itk inhibitors : a patent review , 2010 .
[41] J. Pinilla-Ibarz,et al. Circumventing immune tolerance through epigenetic modification. , 2010, Current pharmaceutical design.
[42] K. Rai,et al. Chronic lymphocytic leukemia: current and emerging treatment approaches. , 2006, Clinical advances in hematology & oncology : H&O.
[43] P. Schwartzberg,et al. Tec family kinases in T lymphocyte development and function. , 2005, Annual review of immunology.
[44] S. Chiplunkar. Immune system and cancer. , 1988, Princess Takamatsu symposia.